• Table 3-1: Worldwide Prevalence of Asthma 2006
  
• Figure 3-1: Worldwide Prevalence of Asthma 2006
  
• Table 3-2: World Population by Age Group 2002-2010
  
• Figure 3-2: World Population by Age Group 2002-2010

Chapter fivE: Market Size and Growth

• Table 5-1: The Worldwide Market for Pulmonary Drug Delivery Technology and
  Pharmaceuticals 2002-2010
  
• Figure 5-1: The Worldwide Market for Pulmonary Drug Delivery Technology and
  Pharmaceuticals 2002-2010
  
• Table 5-2: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug
  Delivery Systems by Type 2002-2010
  
• Figure 5-2: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug
  Delivery Systems Revenues by Type 2002-2010
  
• Table 5-3: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug
  Delivery Technologies Market Share by Type 2002-2010
  
• Figure 5-3: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug
  Delivery Technologies by Type 2006
  
• Figure 5-4: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug
  Delivery Technologies by Type 2010
  
• Table 5-4: The Worldwide Market for Pulmonary Drug Delivery Systems by
  Pharmaceutical and Drug Delivery Component 2002-2010
  
• Table 5-5
  of Revenue by Pharmaceutical and Drug Delivery Component 2002-2010
  
• Figure 5-5
  of Revenue by Pharmaceutical and Drug Delivery Component 2002-2010
  
• Figure 5-6: The Worldwide Market for Pulmonary Drug Delivery Systems
  Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2006
  
• Figure 5-7: The Worldwide Market for Pulmonary Drug Delivery Systems
  Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2010

Chapter six: Competitive and Market Analysis

• Table 6-1: Selected Leading and Emerging Suppliers of Pulmonary Drug
  
• Delivery Technology

Abstract

The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality.

The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers and new product offerings that require advanced drug delivery. Pulmonary drug delivery offers the potential for non-invasive administration of a wide variety of macromolecules. Nearly every biotherapeutic product that treats chronic or long-term illness would benefit from noninvasive delivery by providing a competitive advantage with current therapeutics. This advantage could expand the market for each product or enable new indications to be considered.

Kalorama’s Drug Delivery Markets. Edition 2 Volume III: Pulmonary Delivery Systems, the third volume of Kalorama’s popular series focusing on global drug delivery systems markets, provides the definitive break down of the market for pulmonary delivery system markets. The report covers both pharmaceuticals sold through pulmonary delivery systems and the technologies themselves

The report provides current market size and revenue for the following main categories:

• Inhalation drug delivery
• Intranasal drug delivery

Kalorama believes the future of drug administration by inhalation will expand vastly and be a significant driver in this market. Serious market-watchers who are looking at new products or ways to expand existing products will find this information essential.

As part of its comprehensive cooverage, Kalorama's report includes:

• A Breakdown of Demographics and Trends that will drive pulmonary delivery.
• New Developments including Prodrug Technology, Electrohydrodynamic
  Aerosol Delivery, Oxygen Delivery and Crystallization Technology
• Detailed Discussion of Current Products in pulmonary drug delivery.
• Current Market Size and Forecasts to 2010.
• Review of Pipleline products
• Profiles of Key Companies in the Pulmonary Delivery markets.

As part of Kalorama's trusted information-gathering process, industry executives are interviewed. While government and company data is culled, it is interviews with executives that provide the foundation for market sizes and forecasts.

Kalorama's coverage of the pulmonary drug delivery market includes coverage of the following companies in this field:

• 3M
• Alkermes
• Aradigm
• Elan
• Nastech
• Nektar
• SkyePharma